3 June 2020 - Sponsors seeking US FDA approval for anti-microbial drugs accessed expedited clinical testing and review programs at least as frequently as those seeking approval of non-antimicrobials, according to a study published Tuesday in The Lancet Infectious Diseases.
The median time from investigational new drug application to drug approval was shorter for antimicrobials than other drugs.